Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

a maximum of 20 weeks passed without reaching this goal (unsuccessful tapering of steroids)[1]. In Part II of the study, patients were randomized to either continue receiving ACZ885, or to receive placebo every 4 weeks, until a pre-specified number (37) of flare-events ("flares") had occurred[1].

The primary endpoints were to: a) assess if ACZ885 allows tapering of steroids in at least 25% of SJIA patients (Part I); and b) demonstrate that time to next flare is extended with ACZ885 vs. placebo (Part II)[1].

In Part I of the study (representing 58 patient years), 138 of 177 patients (78%) reported an adverse event (AE), with the most common being nasopharyngitis, headache and cough. Serious adverse events (SAEs) were reported in 15 patients, with the most common being infections, MAS (four cases) or flare-associated events[1]. Five SAEs led to discontinuation, and one patient died of MAS[1]. During Part II, AEs (the most common being arthralgia, cough, nasopharyngitis and pyrexia) were reported by 40 of 50 (80%) ACZ885-treated patients (vs. 35 of 50 [70%] placebo patients previously treated with ACZ885)[1]; and six patients in each arm experienced one or more SAE, which mainly included infections, MAS and flare-associated events[1]. Six patients, all in the placebo arm, discontinued the study due to AEs or SAEs during Part II[1]. One patient died from MAS after study discontinuation in the placebo group.

MAS is a potentially fatal condition known to be associated with SJIA and is characterized by liver abnormalities, bleeding disorders, central nervous system dysfunction and multiple organ failure[4]. Approximately 10% of SJIA patients are diagnosed with MAS, some of whom suffer repeated episodes[4].

About ACZ885ACZ885 is a fully human monoclonal antibody that inhibits IL-1 beta, which is an important part of the body's immune system defenses. Excessive production of IL-1 beta plays a major role in certain inflammatory d
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , September 23, 2014 ... System Transfer     Devices  (CSTD) for ... with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s leading CSTD ... Taiwan , China ... company continues to expand globally, and throughout the ...
(Date:9/23/2014)... Greenville, SC (PRWEB) September 23, 2014 ... ) my third book on healthcare offers a three ... a 21st century healthcare delivery system that would go ... each state’s responsibility regarding the delivery of healthcare.” , ... patient safety has failed to provide discernable progress throughout ...
(Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
(Date:9/22/2014)... SANTA CLARA, Calif. , Sept. 22, 2014 ... ), the leading source of health information, today released ... that provide novel insights regarding physician and patient perspectives ...  Dr. Eric Topol , a leading authority in ... as both Editor-in-Chief of Medscape and Chief Academic Officer ...
Breaking Biology Technology:Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4
... InterMune, Inc. (Nasdaq: ITMN ) today announced that the ... the New Drug Application (NDA) for Esbriet™ (pirfenidone) for the treatment of ... , , , ... is issued by the FDA,s Center for Drug Evaluation and Research when ...
... , May 4 Romark Laboratories announced results from ... nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C.  Study ... late breaking forum of the American Gastroenterological Association Institute (AGA Institute) ... , , , ...
... Microfluidics International Corporation (OTC Bulletin Board: MFLU) announced today the Company will release ... 8:30am ET . , , , ... , , , ... Executive Officer, and Peter F. Byczko , Vice President of Finance and Chief ...
Cached Biology Technology:InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 2InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 3InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 4InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 5Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 2Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 3Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 4Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 5Microfluidics International Corporation to Report First Quarter 2010 Financial Results on May 11, 2010 2Microfluidics International Corporation to Report First Quarter 2010 Financial Results on May 11, 2010 3
(Date:9/22/2014)... As genetic sequencing technologies continue to evolve rapidly, ... need to establish appropriate policies and regulatory frameworks to ... A special policy issue of the Journal of ... edited by experts with the Center for Medical Ethics ... policy makers the tools to jumpstart this process. ...
(Date:9/22/2014)... the Society of Environmental Toxicology and Chemistry (SETAC) held ... prioritize the scientific research needed to understand the risks ... environment. The effort was extended, and results were ... international journal, Integrated Environmental Assessment and Management ... podcast interviewing the lead author of the study, Murray ...
(Date:9/22/2014)... be much more useful in homes, if they could ... the world with cameras and lasers, which have difficulty ... hidden in clutter. A complementary way robots can "sense" ... small ultra-high frequency radio-frequency identification (UHF RFID) tags. Inexpensive ... RFID-equipped robot to search a room for the correct ...
Breaking Biology News(10 mins):Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3Priorities for research on pharmaceutical and personal care products in the environment 2New RFID technology helps robots find household objects 2New RFID technology helps robots find household objects 3
... molecule, a measly angstrom's difference in diameter is a ... a sleek, water-molecule-sized sports car, say scientists at the ... in aquaporins, a class of proteins that form trans-membrane ... They allow for water movement between the cell and ...
... of a piece of the spike-shaped protein that the SARS ... stages of infection. The structure, which shows how the spike ... about how the virus infects cells. The information could also ... exploited by novel antiviral drugs or vaccines. , The ...
... charged lipids and DNA molecules have created a "cookbook" ... will assist doctors and clinicians in the safe and ... the Aug. 9 issue of the Proceedings of the ... careful, comprehensive study to see how negatively charged lipids ...
Cached Biology News:Cells direct membrane traffic by channel width 2Learning how SARS spikes its quarry 2Learning how SARS spikes its quarry 3'Cookbook recipes' would cure disease with nontoxic DNA delivery systems 2
... enzyme-activity assay based on measurenment of enzyme ... antibody coated microtiter plate. The procedure includes ... or controls, 2nd enzyme reaction) separated ... intended for the determination of human enzymaticaly ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... A modified nucleotide structure called a ... of most naturally-occurring eukaryotic mRNAs and ... Analog for a portion of the ... transcription reaction results in the synthesis ...
Biology Products: